Orexo announces that its partner Meda has initiated the launch of EdluarTM in the USA
Uppsala, Sweden, 18 August 2009 - Orexo (STO: ORX) confirms that Meda (STO: MEDA A) has initiated the launch the drug EdluarTM in the United States of America. The launch follows the US Food and Drug Administration’s (FDA) approval in March this year of EdluarTM 5 mg and 10 mg sublingual tablets for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Meda acquired exclusive worldwide commercialization rights for EdluarTM from Orexo in 2008. Orexo will receive royalty payments on Meda’s sales of EdluarTM in the USA. Commenting on the news, Torbjörn Bjerke, CEO of Orexo said: “EdluarTM offers insomnia sufferers a convenient and effective treatment and Meda is well placed to sell EdluarTM in the US market.” EdluarTM is a fast-acting, sublingual formulation of the well-known substance zolpidem. It is based on Orexo’s sublingual technology, involving a tablet placed under the tongue for fast and effective absorption of the active ingredient across the oral mucosa. For more information, please contact: Torbjörn Bjerke, President and CEO, Orexo Tel: +46 (0)708-66 19 90 E-mail: email@example.com Johan Andersson, Investor Relations Manager, Orexo Tel: +46 (o) 702-10 04 51 E-mail: firstname.lastname@example.org About Orexo Orexo is a pharmaceutical company focused on developing drugs for the treatment of pain and inflammation. The company has four products on the market as well as a competitive project portfolio in late stages of development. Sales and product development are mainly carried out through worldwide partnership agreements with larger pharmaceutical companies. Orexo has 128 employees, and has its head office located in Uppsala, Sweden. More information could be found at www.orexo.com. Note: This is information that Orexo AB (publ) is required to disclose pursuant to the Swedish Securities Markets Act. The information was provided for public release on August 18, 2009 at 08:00 CET.